Ivermectin, Fenbendazole and Mebendazole in Lymphoma and Leukemia: 41 Case Reports/Series (August 2026 Update)

Medically Reviewed by: Dr Frank Yap, MD | Written by: OneDayMD Editorial Team | Version 2.0 — Last Updated: August 23, 2026 (originally published February 2026)

Quick Answer

No randomized controlled trials support ivermectin, fenbendazole, or mebendazole as treatments for lymphoma or leukemia. The evidence consists of laboratory/mechanistic rationale, a handful of peer-reviewed case reports — several of which describe an unrelated skin-parasite indication rather than anticancer use — and roughly three dozen unverified, self-reported social media testimonials, most involving concurrent chemotherapy, radiation, or targeted therapy that confounds attribution. These drugs remain investigational and are not guideline-recommended for blood cancers; standard-of-care treatment and clinical-trial enrollment remain the evidence-backed path forward.

Important Disclaimers

• This content is for educational purposes only and does not constitute medical advice. Ivermectin, fenbendazole, and mebendazole are used off-label for cancer and are not FDA-approved for this purpose. Always consult a knowledgeable physician you trust to manage your health. Individual results may vary. Do not self-medicate without proper bloodwork and medical monitoring — misuse can cause serious side effects and drug interactions.
• These agents are, at most, complementary and are not intended to replace conventional, evidence-based cancer treatment such as chemotherapy, radiotherapy, immunotherapy, targeted therapy, or hormone therapy. Any off-label use should be discussed with and supervised by a qualified physician as part of an individualized treatment plan.
• Non-Hodgkin lymphoma, Hodgkin lymphoma, and acute leukemias are potentially life-threatening and can progress rapidly without appropriate treatment. Do not delay or forgo standard, evidence-based cancer therapy. Any complementary or off-label treatment should only be considered in consultation with a qualified oncologist, to complement — not replace — recommended conventional care.
• Affiliate disclosure: Some links on this page (including the "Virtual Doctor" link for physician-supervised care) are affiliate links via The Wellness Company (referral code ONEDAYMD) or Amazon Associates. We may earn a commission at no added cost to you. This does not influence the evidence grading in this article.

Contents

• Introduction
• Evidence Key: How These Reports Are Graded
• Lymphoma Case Reports (28)
• Leukemia Case Reports and Case Series (13)
• Discussion: Biological Plausibility and the Evidence Gap
• Safety Considerations
• Where This Leaves Patients and Clinicians
• Frequently Asked Questions
• Asking AI Assistants About This Topic
• Conclusion

Introduction

Drug repurposing sits at the intersection of curiosity and caution. Ivermectin, fenbendazole, and mebendazole — long-used antiparasitic medications — have accumulated a body of laboratory evidence suggesting anticancer activity across multiple pathways. Meanwhile, a series of case reports and self-reported testimonials involving lymphoma and leukemia patients describe tumor regression, remission, or hematologic normalization after incorporating one or more of these agents into their regimens.

The central question is not whether these reports "prove" efficacy — they cannot, on their own. The more relevant question is whether they represent noise, coincidence, expected response to concurrent conventional treatment, or an early translational signal that warrants structured investigation. This update tries to make that judgment easier by separating the two very different kinds of evidence that had previously been presented side by side as an undifferentiated list of "cases," and by disclosing, case by case, whether standard cancer treatment was also being given at the same time.

Evidence Key: How These Reports Are Graded

Every entry in the tables below is tagged with one of three evidence categories, adapted from the Oxford Centre for Evidence-Based Medicine (CEBM) hierarchy. This is the central improvement in v2.0: the original article presented peer-reviewed case reports and unverified social-media posts side by side under a single numbered "Case" list, which made it easy to mistake one for the other.

Tag	Meaning
CEBM 4	Published, peer-reviewed case report or case series, independently indexed (e.g., in PubMed). Still low on the overall evidence hierarchy — below cohort studies, RCTs, and systematic reviews — but it has passed editorial and peer review.
Non-onc	Published (CEBM 4), but the drug was given for an unrelated non-cancer indication (e.g., a parasitic skin infection) in a patient who happened to have leukemia or lymphoma. Not evidence of anticancer effect.
Unverified	Self-reported on X (Twitter) or Substack by a patient, family member, or treating physician. Not peer-reviewed, not independently verified, and subject to reporting bias (successes are far more likely to be shared than failures). Falls below the formal CEBM hierarchy.

Every "Unverified" row also lists whether conventional treatment (chemotherapy, radiation, targeted therapy) was given at the same time, since that is usually the single biggest confound in interpreting the reported outcome.

The primary source was the OneDayMD case compilation available at https://www.onedaymd.com/2026/02/ivermectin-mebendazole-lymphoma-leukemia.html (August 2026 update)

Lymphoma Case Reports (28)

Ordered most recent first. IVM = ivermectin, FBZ = fenbendazole, MBZ = mebendazole, CR = complete response/remission.

#	Patient	Diagnosis	Concurrent Conventional Tx	Reported Regimen	Follow-up	Reported Outcome	Tier	Source
L1	75F, Thailand	DLBCL	None initially; chemo added later for unrelated Raynaud's	IVM 1mg/kg/d + FBZ 1500mg/d	5 mo	Cancer-free; patient died ~2 mo later of pneumonia after chemo	Unverified	X.com, Aug 2026
L2	72M, Quebec	Hodgkin lymphoma	None reported	IVM 1.0→1.5mg/kg/d + FBZ 888→1500mg/d	20 mo	Complete remission per oncologist	Unverified	X.com, Aug 2026
L3	83M	DLBCL, GCB subtype, stage IVa	None — declined chemo	FBZ 1g/d, self-directed, later tapered	~11 mo	Progressive improvement on serial CT/PET	CEBM 4	Abughanimeh et al., Ann Hematol Oncol, 2020
L4	68M, Colorado	Stage 3 Mantle Cell Lymphoma (neck)	Chemo + immunotherapy added month 7	IVM 25→100mg/d + MBZ 250→1000mg/d + CBD	8 mo	~90% reduction per oncologist	Unverified	X.com, Aug 2026
L5	70F, UK	NHL, B-cell	Concurrent chemo	IVM + FBZ + chemo	5 mo	Near-complete response	Unverified	X.com, May 2026
L6	Female (young adult)	Aggressive Hodgkin lymphoma, post-failed chemo and autologous BMT	None reported at time of protocol	IVM + FBZ + dietary change	>12 mo	Remission with one indeterminate spot on imaging	Unverified	Family account, X.com, Apr 2026
L7	72M, Canada	B-cell Lymphoma	Concurrent chemo (described as "well tolerated")	IVM 1.0→1.5mg/kg/d + FBZ 888→1500mg/d	15 mo	Remission	Unverified	X.com, Mar 2026
L8	85M, Arizona	B-cell Lymphoma	None reported	IVM 1mg/kg/d + FBZ 1000mg/d	10 mo	Remission	Unverified	X.com, Feb 2026
L9	65M, Canada	T-cell Anaplastic Lymphoma, tonsil	Concurrent chemo	IVM 60mg/d + FBZ 888mg/d + chemo	6 mo	Radiographic resolution of nodal masses	Unverified	X.com, Feb 2026
L10	73M, Texas	Stage 4 Marginal Zone Lymphoma	Concurrent bendamustine + rituximab	IVM 48mg/d + FBZ 150mg/d + chemo	6 mo	Complete response on PET and bone marrow biopsy	Unverified	X.com, Feb 2026
L11	59M, Australia	Stage 3 Blastoid Mantle Cell Lymphoma	None reported	IVM 1.5mg/kg/d + FBZ 1500mg/d	4 mo	Clinically stable; oncologist "happy with bloods"	Unverified	X.com, Feb 2026
L12	36M, France	Stage 4 Hodgkin lymphoma	Concurrent chemo	IVM 1.5mg/kg/d + FBZ 1500mg/d + MBZ 1500mg/d	1 mo	Reported better chemo tolerance; too early for response data	Unverified	X.com, Feb 2026
L13	40M, Canada	DLBCL, 9cm/4cm supraspinatus masses	Concurrent R-CHOP (3–6 cycles)	IVM 1mg/kg/d + FBZ 1500mg/d + CBD	8 mo	Complete metabolic response per oncologist	Unverified	X.com, Jan 2026
L14	60M, Massachusetts	Stage 4 DLBCL, bone metastases	None reported	IP6, then IVM 1mg/kg/d + FBZ 1776mg/d	<2 mo	Complete remission reported	Unverified	X.com, Jan 2026
L15	70M, Oklahoma	Stage 4 Follicular Lymphoma, bone metastases	Concurrent R-CHOP (6 cycles)	IVM 1mg/kg/d + FBZ 1000mg/d + CBD	3–6 mo	Clean PET, confirmed on repeat scan	Unverified	X.com, Dec 2025
L16	65M, Canada	T-cell Anaplastic Lymphoma, tonsils	Concurrent chemo	IVM 1mg/kg/d + FBZ 1000mg/d + chemo	3 mo	Resolution reported after 3rd chemo cycle	Unverified	X.com, Nov 2025
L17	Female, UK	NHL, B-cell, high grade	1 cycle chemo, then declined further chemo	FBZ 222→444mg/d	Weeks	PET clear after 1 chemo cycle + fenbendazole	Unverified	X.com, Nov 2025
L18	46M, Canada	Stage II Hodgkin lymphoma, 9x7x11cm mediastinal mass	Concurrent radiation	IVM 1→2mg/kg/d + FBZ 1332mg/d + CBD + melatonin	3 mo	Mass 11cm→2.9cm; oncologist-declared remission	Unverified	X.com, Jun 2025
L19	65M, Tennessee	Early-stage lymphoma (no tissue biopsy — diagnosis by PET only)	None; non-standard supervising provider	IVM + FBZ + colchicine	11 mo	Serial PET scans normalized	Unverified	Journalism (M.B. Pfeiffer), 2025
L20	49M, Georgia	Stage 4 DLBCL, mesentery	None (1 chemo cycle discontinued for toxicity)	IVM 1mg/kg/d + FBZ 1332mg/d	3 mo	Significant improvement on CT; residual disease present	Unverified	X.com, May 2025
L21	60F, Oregon	Mantle Cell Lymphoma, bowel involvement	None reported	IVM 1mg/kg/d + FBZ 888→1332mg/d	3.5 mo	88–96% nodal shrinkage on CT	Unverified	X.com, May 2025
L22	83M, Florida	Stage 3 Follicular Lymphoma	None; oncologist chose "watch and wait"	IVM 1mg/kg/d + FBZ 444mg/d + melatonin	6 mo	"Dramatic" improvement per radiology report; 1 residual node	Unverified	X.com, Apr 2025
L23	94M	Large T-cell Lymphoma, foot mass	None; declined radiation	IVM 12mg/d monotherapy	5 mo	Mass reduced in size (subjective; no imaging confirmation)	Unverified	Family account, X.com, Feb 2025
L24	Female, Europe	Large B-cell Lymphoma	Concurrent R-CHOP (2 cycles)	IVM 1mg/kg/d + MBZ 200mg/d	2 mo	Complete resolution on PET	Unverified	X.com, Nov 2024
L25	Female	Hodgkin lymphoma	None reported (per family account)	Unspecified drugs/supplements + lifestyle change	Unspecified	"Beat" Hodgkin's per family account; no imaging data given	Unverified	Family account, X.com, Dec 2024
L26	Patient, 70s, USA	DLBCL, recently diagnosed	Unclear	High-dose IVM + FBZ	2 wk	Improved bloodwork reported; no imaging/marrow data	Unverified	X.com, Dec 2024
L27	Anonymous	Low-grade lymphoma, neck/chest, recurrence	None; declined repeat chemo	FBZ monotherapy, undisclosed dose	~12 mo	PET and repeat biopsy clear	Unverified	Anonymous online account, 2021
L28	Anonymous ("twin sister")	Stage 2 NHL, B-cell double-hit lymphoma, recurrence	Concurrent 2nd round of chemo	FBZ 222→444mg/d + CBD + curcumin + vitamin E + other supplements	Unspecified	PET clear after 2nd chemo round + regimen	Unverified	Anonymous online account, 2021

↔ Swipe the table sideways to see all columns on mobile

Leukemia Case Reports and Case Series (13)

Covers AML, CLL, CML, and ALL. Rows K7–K11 are the published literature; note that four of these five describe an antiparasitic (non-cancer) indication.

#	Patient	Diagnosis	Concurrent Conventional Tx	Reported Regimen	Follow-up	Reported Outcome	Tier	Source
K1	45F, Romania	AML	None reported	IVM 1.5mg/kg/d + FBZ 1000mg/d	6 mo	Blasts 36%→16%→8% (partial response, not remission)	Unverified	X.com, Jun 2026
K2	60s M, Canada	CLL, relapsed after 2 COVID-19 vaccinations	Concurrent venetoclax + rituximab, after failing acalabrutinib	IVM monotherapy (no fenbendazole)	6 mo	Remission	Unverified	X.com, Apr 2026
K3	56M, Illinois	CML	Not disclosed	IVM + FBZ	6–7 mo	WBC 78.6→7.99→4.27; "major molecular response" (<0.1%) reported	Unverified	X.com, Jan 2026
K4	56M, North Carolina	CLL, Stage 0	None; oncologist chose "watch and wait" (follow-up interval later extended)	Mo. 1–4: IVM 1mg/kg/d + FBZ 1000mg/d. Mo. 5–8: switched to IVM + MBZ 1000mg/d + CBD	8 mo total (two sequential updates, same patient)	WBC 13.3→10.7→10.0; lymphocytes 10.11→4.39	Unverified	X.com, Oct 2025 & Jan 2026
K5	AML patient, diagnosed Oct 2024	AML	Concurrent 2 rounds chemo + venetoclax	IVM 72mg/d + FBZ 1000mg/d (3 days on/4 off)	2 mo	Clear bone marrow biopsy reported	Unverified	X.com, Jan 2025
K6	63M	CLL, "watch and see"	None reported	IVM 70mg/d + MBZ 500→1000mg/d + lactoferrin	~3.5 mo	WBC and lymphocytes trending toward normal range	Unverified	X.com, Jan 2025
K7	1 patient	Adult T-cell Leukemia/Lymphoma (ATL), HTLV-1	Concurrent chemo	Ivermectin + chemo	Not specified	Stabilized and discharged; authors state no firm conclusions on ivermectin's contribution	CEBM 4	Cited in Lai Yuwen et al. review, 2025
K8	Several patients (n not specified)	Leukemia/lymphoma, post-HSCT or in treatment, with Demodex/parasitic skin infection	Standard leukemia/lymphoma treatment (separate from ivermectin)	Ivermectin for the skin infection — not for the cancer	Short-to-intermediate term	Skin symptoms resolved; no anticancer effect confirmed	Non-onc	Cited in Lai Yuwen et al. review, 2025
K9	80F	AML, with crusted scabies	Standard AML treatment (separate from ivermectin)	IVM 9mg (days 1,2,8,9,15) + topical permethrin 5%	2 wk	Skin lesions resolved — a scabies report, not an anticancer report	Non-onc	Cited in Lai Yuwen et al. review, 2025
K10	3 pediatric patients	Refractory AML	Compassionate-use setting; treatment context not fully detailed	IVM 1mg/kg/d, continuous, up to 15 days	Up to 15 days	Well tolerated, no major toxicity — a safety report, not an efficacy trial	CEBM 4	De Castro et al., Leukemia & Lymphoma, 2020
K11	6M	ALL, in remission, with Demodex folliculorum infestation	Standard ALL therapy (separate from ivermectin)	IVM 200mcg/kg + topical permethrin 5%, repeated once	Long-term follow-up	Rash resolved; ALL remained in remission, attributed to standard therapy	Non-onc	Int J Dermatol, 2003

↔ Swipe the table sideways to see all columns on mobile

Discussion: Biological Plausibility and the Evidence Gap

Mechanistic rationale

Mebendazole disrupts microtubules, similar in principle to vincristine — a core drug in many lymphoma regimens. Preclinical studies have also suggested induction of apoptosis in leukemia cell lines, anti-angiogenic effects, Hedgehog pathway inhibition, and potential synergy with chemotherapy. Hematologic malignancies are particularly sensitive to microtubule dynamics, making this mechanistic overlap notable, if unproven in humans.

Ivermectin's proposed anticancer mechanisms include WNT/β-catenin pathway inhibition, PAK1 modulation, induction of mitochondrial dysfunction, and immune signaling modulation. Some leukemia cell-line models demonstrate selective cytotoxicity at higher concentrations than are typically achieved in human plasma at antiparasitic doses.

A recurring issue in repurposing research is pharmacokinetics: in vitro concentrations do not always translate to achievable human plasma levels. Tissue accumulation, tumor microenvironment effects, and immune modulation are variables not fully captured in cell culture models, so the mechanistic plausibility is neither trivial nor definitive.

What the case reports suggest — without overstating it

Across the 41 reports above, several patterns emerge: most patients used ivermectin and/or a benzimidazole alongside standard chemotherapy, radiation, or targeted therapy; some reported rapid tumor regression within months; PET-confirmed remission was described in select lymphoma cases; and in a few early-stage or indolent leukemia cases, hematologic markers reportedly normalized without any concurrent conventional treatment. These are observational, uncontrolled patterns, not controlled outcomes. They raise research-relevant questions — could these drugs act as chemosensitizers, is there subtype-specific responsiveness, and is immune modulation contributing indirectly — but the reports themselves cannot answer them.

The evidence gap: where we stand clinically

The published clinical literature specific to lymphoma and leukemia shows no phase III trials, no randomized controlled trials establishing benefit, only limited early-phase exploration in oncology overall, and no survival endpoint data in hematologic malignancies. In evidence-hierarchy terms, this places the field at the hypothesis-generating stage. Absence of high-level evidence does not equal evidence of absence — but it does mean the untested space is large.

Interpreting the reports through multiple lenses

Possibility	Explanation
Attribution bias	Standard lymphoma therapies like R-CHOP already achieve high remission rates. Improvements seen during combination use may simply reflect the expected response to the concurrent conventional treatment.
Additive or synergistic effect	Preclinical synergy data raise the possibility that these agents could enhance conventional treatment response without being independently curative.
Indolent disease variability	Some leukemias (e.g., early CLL) fluctuate naturally. Marker normalization may reflect disease biology rather than intervention.
Early translational signal	Historically, many oncology breakthroughs began as small observational signals before structured trials validated them.

The present data cannot distinguish among these possibilities — and given how often concurrent conventional treatment appears in the table above, attribution bias deserves the most weight until controlled data exists.

What makes hematologic malignancies an interesting research target

Compared to solid tumors, blood cancers often rely on microtubule-targeting drugs, circulating malignant cells may be more accessible to systemic agents, immune modulation plays a central role in lymphoma biology, and metabolic vulnerabilities may differ from solid tumors. These features make mechanistic exploration in lymphoma and leukemia compelling as a research question — separate from whether the case reports above constitute evidence of benefit.

A research roadmap

If these patterns are to be meaningfully evaluated, the next logical steps include: (1) pharmacokinetic studies confirming tumor-relevant concentrations; (2) in vitro synergy testing with R-CHOP components; (3) phase I dose-finding safety trials in relapsed lymphoma; (4) biomarker stratification (e.g., MYC, WNT activity, metabolic signatures); (5) phase II objective response rate trials; and (6) randomized adjunct studies measuring progression-free survival. Without this progression, the conversation remains anecdotal.

Safety Considerations

One reason these drugs attract attention is their established safety record in short-course antiparasitic use. That said, oncology dosing duration differs substantially from short antiparasitic courses; drug–drug interactions with chemotherapy are under-studied; and long-term hepatic or hematologic effects of extended, high-dose use require structured monitoring. Ivermectin is a P-glycoprotein substrate and is metabolized via CYP3A4 — pathways shared by many chemotherapy agents — which is a theoretical basis for interaction that has not been formally characterized in oncology dosing. The safety advantage seen in antiparasitic use remains a plausible but unproven starting assumption in the cancer context, not an established fact.

Anyone considering off-label use of these agents alongside cancer treatment should do so only with their oncology team's knowledge, with baseline and follow-up bloodwork (including liver function), and with explicit discussion of how the agent may interact with their specific chemotherapy regimen. Physician-supervised care — for example through The Wellness Company's Virtual Doctor service  — is one way to get that conversation started if your current oncologist is unwilling to discuss it.

Where This Leaves Patients and Clinicians

At present: ivermectin, fenbendazole, and mebendazole remain investigational in lymphoma and leukemia. They are not guideline-recommended therapies. Standard-of-care treatment remains the evidence-backed foundation, and clinical trial enrollment remains the safest pathway for exploration. For researchers, these reports represent a cluster of biological plausibility intersecting with real-world experimentation — an intersection that is often where translational oncology begins, but which requires structured trials to move beyond anecdote.

Frequently Asked Questions

Is there clinical trial evidence that ivermectin, fenbendazole, or mebendazole treat lymphoma or leukemia?
No. As of August 2026, there are no completed randomized controlled trials and no phase III data supporting these drugs as treatments for lymphoma or leukemia.

What is the difference between the published case reports and the social-media testimonials in this article?
The published reports went through peer review and are independently indexed. The social-media testimonials are self-reported, not peer-reviewed, not independently verified, and in most cases involve concurrent conventional treatment that confounds attribution.

Can these drugs replace chemotherapy for lymphoma or leukemia?
No. These are potentially life-threatening cancers that can progress rapidly without appropriate treatment. These agents are not guideline-recommended and should not replace standard, evidence-based cancer therapy.

Why do some of the leukemia case reports not actually involve treating leukemia?
Several peer-reviewed reports describe ivermectin given for an unrelated parasitic skin infection (Demodex or scabies) in a patient who happened to have leukemia, with the leukemia itself managed separately. These are legitimate published reports, but they are safety or incidental-finding data, not evidence the drug treated the cancer.

Is it safe to combine ivermectin or fenbendazole with chemotherapy?
This has not been formally studied. Ivermectin is metabolized via CYP3A4 and is a P-glycoprotein substrate, which raises a theoretical interaction risk with some chemotherapy agents. Any off-label use should only happen with oncology team supervision and monitoring.

Should I ask my oncologist about these drugs?
Yes. Any interest in off-label repurposed drugs should be discussed openly with the treating oncology team so potential interactions and the impact on standard treatment planning can be assessed together.

Asking AI Assistants About This Topic

If you're researching this topic using an AI assistant, the quality of the answer depends heavily on how you ask. A few prompts that tend to produce more useful, appropriately calibrated answers:

• Claude: "Summarize the actual evidence quality for ivermectin/fenbendazole/mebendazole in lymphoma and leukemia — separate published case reports from social media testimonials, and flag anything confounded by concurrent chemotherapy."
• ChatGPT: "What does the peer-reviewed literature say about ivermectin or benzimidazole anthelmintics in hematologic cancer — and how does that differ from what's circulating on social media?"
• Gemini: "Find current (2026) clinical trials testing repurposed antiparasitic drugs in lymphoma or leukemia, and tell me their phase and status."
• Perplexity: "What is the CEBM evidence tier for case reports versus case series versus RCTs, and where would an uncontrolled social media testimonial fall relative to that scale?"

In each case, asking the assistant to separate evidence tiers and disclose concurrent treatment — rather than asking "does X cure cancer" — will get you a more useful, appropriately hedged answer.

Conclusion

The 41 case reports and series above neither confirm nor refute the anticancer potential of ivermectin, fenbendazole, and mebendazole in hematologic malignancies. They represent a signal — methodologically limited, and in most cases confounded by concurrent conventional treatment — but not one that is biologically implausible outright. The appropriate scientific response is neither adoption nor rejection. It is investigation. Whether this signal fades under scrutiny or strengthens through structured trials will determine its place in oncology. Until then, it remains an open question, and standard-of-care treatment, discussed openly with your oncology team, remains the evidence-backed foundation of care.

Primary source 

• https://www.onedaymd.com/2026/02/ivermectin-mebendazole-lymphoma-leukemia.html (August 2026 update)

Related

• Fenbendazole, Ivermectin and Mebendazole for Cancer: A Case Series of 760+ Case Reports (August 2026 Update)
• Dr William Makis Ivermectin Protocol 2026 — Complete Guide + Patient Outcomes